This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harding, M., Northcott, D., Smyth, J. et al. Phase II evaluation of mitozolomide in ovarian cancer. Br J Cancer 57, 113–114 (1988). https://doi.org/10.1038/bjc.1988.21
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.21
This article is cited by
-
A clinical and pharamcological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue
Cancer Chemotherapy and Pharmacology (1992)
-
Relationship between the pharmacokinetics and toxicity of mitozolomide
Cancer Chemotherapy and Pharmacology (1990)